C4 Therapeutics, Inc.
CCCC
Rank in Stocks
#13482
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on... C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutic candidates. Its core strategy involves degrading proteins implicated in disease, addressing a range of conditions including cancer, neurodegenerative disorders, and other illnesses. The company's primary drug candidate, CFT7455, is an orally administered MonoDAC degrader of the IKZF1 and IKZF3 proteins. This compound is currently undergoing Phase 1/2 clinical trials for the treatment of multiple myeloma and various non-Hodgkin lymphomas, such as peripheral T-cell lymphoma and mantle cell lymphoma. Additionally, C4 Therapeutics is advancing several other programs: CFT8634, an orally bioavailable BiDAC degrader targeting the BRD9 protein, for potential use in synovial sarcoma and SMARCB1-deleted solid tumors. CFT1946, an orally administered BiDAC degrader designed to act on the V600X mutant BRAF, aimed at indications like melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies. CFT8919, an orally available, allosteric, and mutant-selective BiDAC degrader specifically targeting epidermal growth factor receptor (EGFR) with an L858R mutation in NSCLC. Their early-stage pipeline also features RET degraders for various forms of cancer. C4 Therapeutics, Inc. has formed strategic partnerships with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Biogen MA, Inc., and Calico Life Sciences LLC. The company was established in 2015 and its headquarters are located in Watertown, Massachusetts.
Share Price
$3.15
Last synced: 2026-11-09
Market Cap
$387.53M
Change (1 day)
1.61%
Change (1 year)
27.02%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade C4 Therapeutics, Inc. (CCCC)
Category
Healthcare
EPS for C4 Therapeutics, Inc. (CCCC)
EPS as of September 2026 TTM: $-0.72
According to C4 Therapeutics, Inc.'s latest financial reports, its current EPS (TTM) is $-0.72. At the end of 2025 the company had an EPS of $-1.27, an increase over its 2024 EPS of $-1.52.
EPS history for C4 Therapeutics, Inc. from 2018 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.72 | -43.31% |
| 2025 | $-1.27 | -16.45% |
| 2024 | $-1.52 | -43.07% |
| 2023 | $-2.67 | 1.91% |
| 2022 | $-2.62 | 43.96% |
| 2021 | $-1.82 | 18.18% |
| 2020 | $-1.54 | 94.94% |
| 2019 | $-0.79 | -25.47% |
| 2018 | $-1.06 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -2,275.00% |
US
|
|
| $-7.07 | 881.94% |
US
|
|
| $-5.29 | 634.72% |
AU
|
|
| $12.88 | -1,888.90% |
BE
|
|
| $21.56 | -3,094.44% |
NL
|
Questions about C4 Therapeutics, Inc.'s earnings per share (EPS)
What is C4 Therapeutics, Inc.'s earnings per share (EPS)?
C4 Therapeutics, Inc.'s earnings per share (EPS) over the last twelve months is $-0.72, as of Sep 2026.
What was C4 Therapeutics, Inc.'s earnings per share (EPS) in 2025?
In 2025, C4 Therapeutics, Inc.'s earnings per share (EPS) was $-1.27, compared with $-1.52 in 2024.
How has C4 Therapeutics, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, C4 Therapeutics, Inc.'s earnings per share (EPS) was highest in 2025 ($-1.27) and lowest in 2023 ($-2.67).
How does C4 Therapeutics, Inc.'s earnings per share (EPS) compare with similar companies?
C4 Therapeutics, Inc.'s earnings per share (EPS) ($-0.72) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.